These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 14504072)

  • 1. Imatinib mesylate elicits positive clinical response in atypical chronic myeloid leukemia involving the platelet-derived growth factor receptor beta.
    Garcia JL; Font de Mora J; Hernandez JM; Queizan JA; Gutierrez NC; Hernandez JM; San Miguel JF
    Blood; 2003 Oct; 102(7):2699-700. PubMed ID: 14504072
    [No Abstract]   [Full Text] [Related]  

  • 2. Pregnancy in patients with chronic myeloid leukemia treated with imatinib.
    Yilmaz M; Demirhan O; Kuçukosmanoglu E; Pehlivan M; Okan V; Balat O; Pehlivan S
    Leuk Lymphoma; 2007 Dec; 48(12):2454-6. PubMed ID: 18067024
    [No Abstract]   [Full Text] [Related]  

  • 3. Chronic myeloid leukemia. Sceptical scientists.
    Druker BJ
    Lancet; 2001 Dec; 358 Suppl():S11. PubMed ID: 11784560
    [No Abstract]   [Full Text] [Related]  

  • 4. Chromosomal abnormalities in Ph- cells of patients on imatinib.
    McMullin MF; Humphreys M; Byrne J; Russell NH; Cuthbert RJ; O'Dwyer ME
    Blood; 2003 Oct; 102(7):2700-1; author reply 2701. PubMed ID: 14504073
    [No Abstract]   [Full Text] [Related]  

  • 5. hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia.
    Bazeos A; Marin D; Reid AG; Gerrard G; Milojkovic D; May PC; de Lavallade H; Garland P; Rezvani K; Apperley JF; Goldman JM; Foroni L; Khorashad JS
    Leukemia; 2010 Jun; 24(6):1243-5. PubMed ID: 20445576
    [No Abstract]   [Full Text] [Related]  

  • 6. Imatinib mesylate: a new pill for chronic myelogenous leukemia.
    Parmar KK; King RS
    Cancer Pract; 2001; 9(5):263-5. PubMed ID: 11879324
    [No Abstract]   [Full Text] [Related]  

  • 7. [Treatment of chronic myelogenous leukemia by using imatinib].
    Jinnai I
    Nihon Naika Gakkai Zasshi; 2005 Sep; 94(9):1819-24. PubMed ID: 16223141
    [No Abstract]   [Full Text] [Related]  

  • 8. Chromosomal abnormalities in chronic myeloid leukemia: evidence of a hierarchy in imatinib treated cells.
    Ostro D; Cheung K; Kamel-Reid S; Lipton JH
    Leuk Lymphoma; 2007 May; 48(5):1029-31. PubMed ID: 17487749
    [No Abstract]   [Full Text] [Related]  

  • 9. Discontinuing imatinib in chronic myeloid leukemia: don't try this at home.
    Mattison R; Larson RA
    Leuk Lymphoma; 2009 Jun; 50(6):868-70. PubMed ID: 19455466
    [No Abstract]   [Full Text] [Related]  

  • 10. Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate.
    Arora B; Kumar L; Sharma A; Wadhwa J; Kochupillai V
    Ann Oncol; 2004 Feb; 15(2):358-9. PubMed ID: 14760137
    [No Abstract]   [Full Text] [Related]  

  • 11. An activating KRAS mutation in imatinib-resistant chronic myeloid leukemia.
    Agarwal A; Eide CA; Harlow A; Corbin AS; Mauro MJ; Druker BJ; Corless CL; Heinrich MC; Deininger MW
    Leukemia; 2008 Dec; 22(12):2269-72. PubMed ID: 18509354
    [No Abstract]   [Full Text] [Related]  

  • 12. Imatinib mesylate in the treatment of chronic myelogenous leukemia.
    Borthakur G; Cortes JE
    Int J Hematol; 2004 Jun; 79(5):411-9. PubMed ID: 15239390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.
    Wolff NC; Veach DR; Tong WP; Bornmann WG; Clarkson B; Ilaria RL
    Blood; 2005 May; 105(10):3995-4003. PubMed ID: 15657179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concomitant myelodysplastic syndrome and chronic myeloid leukaemia: treatment outcomes with imatinib mesylate.
    Mesa RA; Steensma DP; Hoyer J; Ketterling RP
    Br J Haematol; 2003 Oct; 123(2):366-7. PubMed ID: 14531922
    [No Abstract]   [Full Text] [Related]  

  • 15. Imatinib for chronic myeloid leukaemia: a NICE mess.
    Barbour V
    Lancet; 2001 Nov; 358(9292):1478. PubMed ID: 11705557
    [No Abstract]   [Full Text] [Related]  

  • 16. Imatinib mesylate noncompliance simulating chronic myeloid leukemia resistance.
    Sandoval C; Giamelli J; Jayabose S
    J Pediatr Hematol Oncol; 2003 Jun; 25(6):507-8. PubMed ID: 12794534
    [No Abstract]   [Full Text] [Related]  

  • 17. Imatinib in chronic myeloid leukemia elderly patients.
    Gugliotta G; Castagnetti F; Palandri F; Baccarani M; Rosti G
    Aging (Albany NY); 2011 Dec; 3(12):1125-6. PubMed ID: 22203437
    [No Abstract]   [Full Text] [Related]  

  • 18. Discontinuation of imatinib therapy after achieving a molecular response.
    Cortes J; O'Brien S; Kantarjian H
    Blood; 2004 Oct; 104(7):2204-5. PubMed ID: 15377577
    [No Abstract]   [Full Text] [Related]  

  • 19. Chronic myeloid leukemia presenting with extramedullary disease as massive ascites responding to imatinib mesylate.
    Aleem A; Siddiqui N
    Leuk Lymphoma; 2005 Jul; 46(7):1097-9. PubMed ID: 16019565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
    Hardling M; Wei Y; Palmqvist L; Swolin B; Stockelberg D; Gustavsson B; Ekeland-Sjöberg K; Wadenvik H; Ricksten A
    Med Oncol; 2004; 21(4):349-58. PubMed ID: 15579919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.